Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma
NCT00084617Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2004
- Primary completion
- Oct 2008
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab and capecitabine in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by National Cancer Institute. Primary endpoint: Response Rate at 12 weeks. Started Mar 2004; status: completed.
02
Drugs
oxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabcapecitabine
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00084617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00084617.